Literature DB >> 32052249

Conducting a Pilot Randomized Controlled Trial on a Medical Inpatient Unit Utilizing Cognitive Remediation Therapy for Adolescents with Restrictive Eating Disorders: Protocol Updates and Reflections on Feasibility.

C Alix Timko1,2, Kathleen Kara Fitzpatrick3, Tiffanie Goulazian4, Devin Kirby4, Elizabeth Parks4, Leela Morrow4,5, Alexander M Scharko4,5, Rebecka Peebles5,6.   

Abstract

We conducted a pilot randomized control trial (RCT) to simultaneously examine the feasibility of effectively implementing Cognitive Remediation Therapy (CRT) for adolescents with anorexia nervosa (AN) during medical hospitalization at a single-site hospital center. Employment of this protocol occurred on a general medical unit with diverse medical admitting diagnoses, not an eating disorder floor of a hospital and not part of a structured inpatient anorexia nervosa treatment program. This was the first time an RCT for a psychosocial intervention was implemented on this unit with patients with eating disorders. Here, we describe the process of piloting the study, including modifications that needed to be made to the original protocol. We also describe the feedback from major stakeholders regarding the process of conducting the pilot study. We summarize lessons learned and steps to take for smooth integration of an RCT of a therapeutic intervention on medical unit.Trial registration: ClinicalTrials.gov Identifier NCT02883413.

Entities:  

Keywords:  Adolescents; Anorexia nervosa; Cognitive remediation therapy; Pilot and feasibility study

Mesh:

Year:  2020        PMID: 32052249     DOI: 10.1007/s10880-020-09704-w

Source DB:  PubMed          Journal:  J Clin Psychol Med Settings        ISSN: 1068-9583


  1 in total

1.  Young people and parents' views towards individual cognitive remediation therapy-qualitative findings from a feasibility randomised controlled trial.

Authors:  Lucia Giombini; Sophie Nesbitt; Rutendo Kusosa; Katerina Hinallas; Cleo Fabian; Abigail Easter; Kate Tchanturia
Journal:  Eat Weight Disord       Date:  2022-01-17       Impact factor: 3.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.